HMGCLL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The present study demonstrates that the HMGCLL1 genetic variant is a powerful predictive biomarker for intrinsic sensitivity to TKI therapy that correlates with DMR rate in CML patients.